cers [see dosage and administration (2.4) ]. 7.2 v 2 -receptor agonist as a v 2 -receptor antagonist, tolvaptan will interfere with the v 2 -agonist activity of desmopressin (ddavp). avoid concomitant use of jynarque with a v 2 -agonist.

nificant or irreversible liver injury, assess alt, ast and bilirubin prior to initiation of jynarque, at 2 weeks and 4 weeks after initiation, then monthly for 18 months and every 3 months thereafter. at the onset of signs or symptoms consistent with hepatic injury or if alt, ast, or bilirubin increase to >2 times uln, immediately discontinue jynarque, obtain repeat tests as soon as possible (within 48 to 72 hours), and continue testing as appropriate. if laboratory abnormalities stabilize or resolve, jynarque may be reinitiated with increased frequency of monitoring as long as alt and ast remain below 3 times uln. do not restart jynarque in patients who experience signs or symptoms consistent with hepatic injury or whose alt or ast ever exceeds 3 times uln during treatment with tolvaptan, unless there is another explanation for liver injury and the injury has resolved. in patients with a stable, low baseline ast or alt, an increase above 2 times baseline, even if less than 2 times upper limit of normal, may indicate early liver injury. such elevations may warrant treatment suspension and prompt (48 to 72 hours) re-evaluation of liver test trends prior to reinitiating therapy with more frequent monitoring. 5.2 jynarque rems program jynarque is available only through a restricted distribution program under a risk evaluation and mitigation strategy (rems) called the jynarque rems program, because of the risks of liver injury [see warnings and precautions (5.1) ] . notable requirements of the jynarque rems program include the following: prescribers must be certified by enrolling in the rems program. prescribers must inform patients receiving jynarque about the risk of hepatotoxicity associated with its use and how to recognize the signs and symptoms of hepatotoxicity and the appropriate actions to take if it occurs. patients must enroll in the rems program and comply with ongoing monitoring requirements [see warnings and precautions (5.1) ] . pharmacies must be certified by enrolling in the rems program and must only dispense to patients who are authorized to receive jynarque. further information, including a list of qualified pharmacies/distributors, is available at www.jynarquerems.com or by telephone at 1-877-726-7220. 5.3 hypernatremia, dehydration and hypovolemia jynarque increases free water clearance and, as a result, may cause dehydration, hypovolemia and hypernatremia. therefore, ensure abnormalities in sodium concentrations are corrected prior to initiation of therapy. instruct patients to drink water when thirsty, and throughout the day and night if awake. monitor for weight loss, tachycardia and hypotension because they may signal dehydration. in the two double-blind, placebo-controlled trials of patients with adpkd, hypernatremia (defined as any serum sodium concentration >150 meq/l) was observed in 4.0% versus 0.6% and 1.4% versus 0% of tolvaptan-treated versus placebo-treated patients, respectively. the rate of dehydration and hypovolemia in the two studies was 2.1% versus 0.7% and 2.3% versus 0.4% for tolvaptan-treated versus placebo-treated patients, respectively. during jynarque therapy, if serum sodium increases above normal range or the patient becomes hypovolemic or dehydrated and fluid intake cannot be increased, then suspend jynarque until serum sodium, hydration status and volume status is within the normal range. 5.4 co-administration with inhibitors of cyp 3a concomitant use of jynarque with drugs that are moderate or strong cyp 3a inhibitors (e.g., ketoconazole, itraconazole, lopinavir/ritonavir, indinavir/ritonavir, ritonavir, and conivaptan) increases tolvaptan exposure [see drug interactions (7.1) and clinical pharmacology (12.3) ] . use with strong cyp 3a inhibitors is contraindicated; dose reduction of jynarque is recommended for patients while taking moderate cyp 3a inhibitors [see dosage and administration (2.4) and contraindications (4) ].

months and every 3 months thereafter . monitor for concurrent symptoms that may indicate liver injury [see warnings and precautions (5.1) ] . 2.3 missed doses if a dose of jynarque is not taken at the scheduled time, take the next dose at its scheduled time. 2.4 co-administration with cyp 3a inhibitors cyp 3a inhibitors concomitant use of strong cyp 3a inhibitors is contraindicated [see contraindications (4) and warnings and precautions (5.4) ] . in patients taking concomitant moderate cyp 3a inhibitors, reduce the dose of jynarque per table 1. consider further reductions if patients cannot tolerate the reduced dose [see warnings and precautions (5.4) and drug interactions (7.1) ] . interrupt jynarque temporarily for short term therapy with moderate cyp 3a inhibitors if the recommended reduced doses are not available. table 1: dose adjustment for patients taking moderate cyp 3a inhibitors standard morning and afternoon dose (mg) dose (mg) with moderate cyp 3a inhibitors 90 mg and 30 mg 45 mg and 15 mg 60 mg and 30 mg 30 mg and 15 mg 45 mg and 15 mg 15 mg and 15 mg

ed in over 3000 patients with adpkd. long-term, placebo-controlled safety information of jynarque in adpkd is principally derived from two trials where 1,413 subjects received tolvaptan and 1,098 received placebo for at least 12 months across both studies. tempo 3:4 -nct00428948: a phase 3, double-blind, placebo-controlled, randomized trial in early, rapidly-progressing adpkd the tempo3:4 trial employed a two-arm, 2:1 randomization to tolvaptan or placebo, titrated to a maximally-tolerated total daily dose of 60 to 120 mg. a total of 961 subjects with rapidly progressing adpkd were randomized to jynarque. of these, 742 (77%) subjects who were treated with jynarque remained on treatment for at least 3 years. the average daily dose in these subjects was 96 mg daily. adverse events that led to discontinuation were reported for 15.4% (148/961) of subjects in the jynarque group and 5.0% (24/483) of subjects in the placebo group. aquaretic effects were the most common reasons for discontinuation of jynarque. these included pollakiuria, polyuria, or nocturia in 63 (6.6%) subjects treated with jynarque compared to 1 subject (0.2%) treated with placebo. table 2 lists the adverse reactions that occurred in at least 3% of adpkd subjects treated with jynarque and at least 1.5% more than on placebo. table 2: tempo 3:4, treatment emergent adverse reactions in ≥3% of jynarque treated subjects with risk difference ≥1.5%, randomized period adverse reaction tolvaptan (n=961) placebo (n=483) number of subjects proportion (%) 100× (number of subjects with an adverse event/n) annualized rate 100× (number of subjects with an adverse event/total subject years of drug exposure) number of subjects proportion (%) annualized rate increased urination increased urination includes micturition urgency, nocturia, pollakiuria, polyuria 668 69.5 28.6 135 28.0 10.3 thirst thirst includes polydipsia and thirst 612 63.7 26.2 113 23.4 8.7 dry mouth 154 16.0 6.6 60 12.4 4.6 fatigue 131 13.6 5.6 47 9.7 3.6 diarrhea 128 13.3 5.5 53 11.0 4.1 dizziness 109 11.3 4.7 42 8.7 3.2 dyspepsia 76 7.9 3.3 16 3.3 1.2 decreased appetite 69 7.2 3.0 5 1.0 0.4 abdominal distension 47 4.9 2.0 16 3.3 1.2 dry skin 47 4.9 2.0 8 1.7 0.6 rash 40 4.2 1.7 9 1.9 0.7 hyperuricemia 37 3.9 1.6 9 1.9 0.7 palpitations 34 3.5 1.5 6 1.2 0.5 reprise-nct02160145: a phase 3, randomized-withdrawal, placebo-controlled, double-blind, trial in late stage 2 to early stage 4 adpkd the reprise trial employed a 5-week single-blind titration and run-in period for jynarque prior to the randomized double-blind period. during the jynarque titration and run-in period, 126 (8.4%) of the 1496 subjects discontinued the study, 52 (3.5%) were due to aquaretic effects and 10 (0.7%) were due to liver test findings. because of this run-in design, the adverse reaction rates observed during the randomized period are not described. liver injury: in the two double-blind, placebo-controlled trials, alt elevations >3 times uln were observed at an increased frequency with jynarque compared with placebo (4.9% [80/1637] versus 1.1% [13/1166], respectively) within the first 18 months after initiating treatment and increases usually resolved within 1 to 4 months after discontinuing the drug. 6.2 postmarketing experience the following adverse reactions have been identified during post-approval use of tolvaptan. because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to estimate their frequency reliably or establish a causal relationship to drug exposure. hepatobiliary disorders: liver failure requiring transplant immune system disorders: anaphylaxis

cers [see dosage and administration (2.4) ]. 7.2 v 2 -receptor agonist as a v 2 -receptor antagonist, tolvaptan will interfere with the v 2 -agonist activity of desmopressin (ddavp). avoid concomitant use of jynarque with a v 2 -agonist.

proximately 3-times the human exposure (see data ). advise pregnant women of the potential risk to the fetus. the estimated background risk of major birth defects and miscarriage for the indicated population is unknown. all pregnancies have a background risk of birth defect, loss, or other adverse outcomes. the estimated background risk of major birth defects and miscarriage in the u.s. general population is 2 to 4% and 15 to 20% of clinically recognized pregnancies, respectively. data animal data oral administration of tolvaptan during the period of organogenesis in sprague-dawley rats produced no evidence of teratogenesis at doses up to 100 mg/kg/day. lower body weights and delayed ossification were seen at 1000 mg/kg, which is approximately 17-times the exposure in humans at the 90/30 mg dose (auc 24h 6570 h∙ng/ml). the fetal effects are likely secondary to maternal toxicity (decreased food intake and low body weights). in a prenatal and postnatal study in rats, tolvaptan had no effect on physical development, reflex function, learning ability or reproductive performance at doses up to 1000 mg/kg/day. in new zealand white rabbits, placental transfer was demonstrated with c max values in the yolk sac fluid approximating 22.7% of the value in maternal rabbit serum. in embryo-fetal studies, teratogenicity (microphthalmia, embryo-fetal mortality, cleft palate, brachymelia and fused phalanx) was evident in rabbits at 1000 mg/kg (approximately 3 times the exposure at the 90/30 mg dose). body weights and food consumption were lower in dams at all doses, equivalent to 0.6 to 3- times the human exposure at the 90/30 mg dose. 8.2 lactation risk summary there are no data on the presence of tolvaptan in human milk, the effects on the breastfed infant, or the effects on milk production. tolvaptan is present in rat milk. when a drug is present in animal milk, it is possible that the drug will be present in human milk, but relative levels may vary (see data ) . because of the potential for serious adverse reactions, including liver toxicity, electrolyte abnormalities (e.g., hypernatremia), hypotension, and volume depletion in breastfed infants, advise women not to breastfeed during treatment with jynarque. data in lactating rats administration of radiolabeled tolvaptan, lacteal radioactivity concentrations reached the highest level at 8 hours after administration and then decreased gradually with time with a half-life of 27.3 hours. the level of activity in milk ranged from 1.5- to 15.8-fold those in blood over the period of 72 hours post-dose. in a prenatal and postnatal study in rats, maternal toxicity was noted at 100 mg/kg/day or higher (≥4.4 times the human exposure at the 90/30 mg dose). increased perinatal death and decreased body weight of the offspring were observed during the lactation period and after weaning at approximately 17.3 times the human exposure at the 90/30 mg dose. 8.4 pediatric use safety and effectiveness of jynarque in pediatric patients have not been established. 8.5 geriatric use clinical studies of tolvaptan did not include sufficient numbers of subjects aged 65 years old and over to determine whether they respond differently from younger subjects. other reported clinical experience has not identified differences in responses between the elderly and younger patients. in general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. 8.6 use in patients with hepatic impairment because of the risk of serious liver injury, use is contraindicated in patients with a history, signs or symptoms of significant liver impairment or injury. this contraindication does not apply to uncomplicated polycystic liver disease which was present in 60% and 66% of patients in tempo 3:4 and reprise, respectively. no specific exclusion for hepatic impairment was implemented in tempo 3:4. however, reprise excluded patients with adpkd who had hepatic impairment or liver function abnormalities other than that expected for adpkd with typical cystic liver disease [see contraindications (4) ]. 8.7 use in patients with renal impairment efficacy studies included patients with normal and reduced renal function [see clinical studies (14) ] . tempo 3:4 required patients to have an estimated creatinine clearance ≥ 60 ml/min, while reprise included patients with egfr ckd-epi 25 to 65 ml/min/1.73m 2 .

ated background risk of major birth defects and miscarriage for the indicated population is unknown. all pregnancies have a background risk of birth defect, loss, or other adverse outcomes. the estimated background risk of major birth defects and miscarriage in the u.s. general population is 2 to 4% and 15 to 20% of clinically recognized pregnancies, respectively. data animal data oral administration of tolvaptan during the period of organogenesis in sprague-dawley rats produced no evidence of teratogenesis at doses up to 100 mg/kg/day. lower body weights and delayed ossification were seen at 1000 mg/kg, which is approximately 17-times the exposure in humans at the 90/30 mg dose (auc 24h 6570 h∙ng/ml). the fetal effects are likely secondary to maternal toxicity (decreased food intake and low body weights). in a prenatal and postnatal study in rats, tolvaptan had no effect on physical development, reflex function, learning ability or reproductive performance at doses up to 1000 mg/kg/day. in new zealand white rabbits, placental transfer was demonstrated with c max values in the yolk sac fluid approximating 22.7% of the value in maternal rabbit serum. in embryo-fetal studies, teratogenicity (microphthalmia, embryo-fetal mortality, cleft palate, brachymelia and fused phalanx) was evident in rabbits at 1000 mg/kg (approximately 3 times the exposure at the 90/30 mg dose). body weights and food consumption were lower in dams at all doses, equivalent to 0.6 to 3- times the human exposure at the 90/30 mg dose.

owth of total kidney volume and the rate of formation and enlargement of kidney cysts. tolvaptan metabolites have no or weak antagonist activity for human v 2 -receptors compared with tolvaptan. 12.2 pharmacodynamics in healthy subjects or patients with egfrs as low as 10 ml/min/1.73m 2 receiving a single dose of tolvaptan, the onset of the aquaretic effects occurs within 1 to 2 hours post-dose. in healthy subjects, single doses of 60 mg and 90 mg produce a peak effect of about a 9 ml/min increase in urine excretion rate is observed between 4 and 8 hours post-dose. higher doses of tolvaptan do not increase the peak effect in urine excretion rate but sustain the effect for a longer period of time. urine excretion rate returns to baseline within 24 hours following the maximum recommended 90 mg dose of tolvaptan. changes in free water clearance mirror the changes in urine excretion rate. increased free water clearance causes an increase in serum sodium concentration unless fluid intake is increased to match urine output. increases in urine excretion rate and free water clearance are positively correlated with baseline glomerular filtration rate with increases in both values observed in patients with creatinine clearance as low as 15 ml/min. with the recommended split-dose regimens, tolvaptan inhibits vasopressin from binding to the v 2 -receptor in the kidney for the entire day, as indicated by increased urine output and decreased urine osmolality. following a 90/30 mg split-dose regimen in patients with egfr >60 ml/min/1.73 m 2 , the change in mean daily urine volume was about 4 l for a mean total daily volume of about 7 l. in patients with egfr <30 ml/min/1.73 m 2 , the mean change in daily urine volume was about 2 l for a total daily urine volume of about 5 l. plasma concentrations of native avp may increase (avg. 2 to 9 pg/ml) with tolvaptan treatment and return to baseline levels when treatment is stopped. during tolvaptan treatment, small changes in renal function are expected and the changes are independent of baseline renal function. glomerular filtration rate is decreased about 6% to 10% and uric acid clearance is decreased about 20% to 25%. percent changes in renal plasma flow are highly correlated to percent changes in gfr. these changes are reversed upon discontinuation of tolvaptan. cardiac electrophysiology no prolongation of the qt interval was observed with tolvaptan following multiple doses of 300 mg/day for 5 days. 12.3 pharmacokinetics in healthy subjects, the pharmacokinetics of tolvaptan after single doses of up to 480 mg and multiple doses up to 300 mg once daily have been studied. in adpkd patients, single doses up to 120 mg and multiple split-doses up to 90/30 mg have been studied. absorption: in healthy subjects, peak concentrations of tolvaptan are observed between 2 and 4 hours post-dose. peak concentrations increase less than dose proportionally with doses greater than 240 mg. the absolute bioavailability of tolvaptan decreases with increasing doses. the absolute bioavailability of tolvaptan following an oral dose of 30 mg is 56% (range 42 to 80%). co-administration of 90 mg jynarque with a high-fat meal (~1000 calories, of which 50% are from fat) doubles peak concentrations but has no effect on the auc of tolvaptan; tolvaptan may be administered with or without food. distribution: tolvaptan binds to both albumin and α1-acid glycoprotein and the overall protein binding is >98%; binding is not affected by disease state. the volume of distribution of tolvaptan is about 3 l/kg. the pharmacokinetic properties of tolvaptan are stereospecific, with a steady-state ratio of the s-(-) to the r-(+) enantiomer of about 3. when administered as multiple once-daily 300 mg doses to healthy subjects or as split-dose regimens to patients with adpkd, tolvaptan's accumulation factor is <1.2. there is marked inter-subject variation in peak and average exposure to tolvaptan with a percent coefficient of variation ranging between 30 and 60%. metabolism and elimination: tolvaptan is metabolized almost exclusively by cyp 3a. fourteen metabolites have been identified in plasma, urine and feces; all but one were also metabolized by cyp 3a and none are pharmacodynamically active. after oral administration of radiolabeled tolvaptan, tolvaptan was a minor component in plasma representing 3% of total plasma radioactivity; the oxobutyric acid metabolite was present at 52.5% of total plasma radioactivity with all other metabolites present at lower concentrations than tolvaptan. the oxobutyric acid metabolite shows a plasma half-life of ~180 h. about 40% of radioactivity was recovered in urine (<1% as unchanged tolvaptan) and 59% in feces (19% as unchanged tolvaptan). following intravenous infusion, tolvaptan half-life is approximately 3 hours. following single oral doses to healthy subjects, the estimated half-life of tolvaptan increases from 3 hours for a 15 mg dose to approximately 12 hours for 120 mg and higher doses due to more prolonged absorption of tolvaptan at higher doses; apparent clearance is approximately 4 ml/min/kg and does not appear to change with increasing dose. specific populations age, gender and race age, gender and race have no effect on tolvaptan pharmacokinetics. hepatic impairment in studies involving patients with hepatic impairment (child-pugh class a-c), but without adpkd; moderate (class a, b) or severe (class c) hepatic impairment decreases the clearance and increases the volume of distribution of tolvaptan. renal impairment in subjects with creatinine clearances ranging from 10 to 124 ml/min administered a single dose of 60 mg tolvaptan, the auc and c max of plasma tolvaptan was increased 90% and 10%, respectively, for subjects with clearances of <30 ml/min compared to subjects with clearances >60 ml/min [see use in special populations (8.7) ]. in adpkd patients with estimated creatinine clearance >60 ml/min, pharmacokinetics were similar to healthy subjects. drug interaction studies: impact of other drugs on tolvaptan strong cyp 3a inhibitors tolvaptan's cmax and auc were, respectively, 3.5 times and 5.4 times as high following ketoconazole 200 mg given one day prior to and concomitantly with 30 mg tolvaptan. moderate cyp 3a4 inhibitors fluconazole: fluconazole 400 mg given one day prior and 200 mg given concomitantly produced an 80% and 200% increase in tolvaptan c max and auc, respectively. grapefruit juice: when 60 mg tolvaptan was taken with 240 ml regular strength grapefruit juice, tolvaptan c max and auc increased 90% and 60%, respectively. cyp 3a inducers rifampin: rifampin 600 mg once daily for 7 days followed by a single 240 mg dose of tolvaptan decreased both tolvaptan c max and auc about 85%. other drugs co-administration of lovastatin, digoxin, furosemide, and hydrochlorothiazide with tolvaptan has no clinically relevant impact on the exposure to tolvaptan. impact of tolvaptan on other drugs cyp 3a substrates co-administration of lovastatin and tolvaptan increases the auc of lovastatin and its active metabolite lovastatin-β hydroxy acid by 40% and 30%, respectively. these are non-clinically significant increases in exposure. p-gp substrates digoxin: digoxin 0.25 mg was administered once daily for 12 days. tolvaptan 60 mg, was co-administered once daily on days 8 to 12. digoxin c max and auc were increased 30% and 20%, respectively. transporter substrates tolvaptan is a substrate of p-gp and an inhibitor of p-gp and bcrp. the oxobutyric acid metabolite of tolvaptan is an inhibitor of oatp1b1 and oat3. co-administration of tolvaptan with rosuvastatin (bcrp substrate) did not have a clinically significant effect on rosuvastatin exposure. rosuvastatin c max and auc t increased 54% and 69%, respectively. administration of rosuvastatin (oatp1b1 substrate) or furosemide (oat3 substrate) to healthy subjects with elevated oxobutyric acid metabolite plasma concentrations did not meaningfully alter the pharmacokinetics of rosuvastatin or furosemide. other drugs co-administration of tolvaptan did not meaningfully alter the pharmacokinetics of warfarin, furosemide, hydrochlorothiazide, or amiodarone (or its active metabolite, desethylamiodarone).

ng is not affected by disease state. the volume of distribution of tolvaptan is about 3 l/kg. the pharmacokinetic properties of tolvaptan are stereospecific, with a steady-state ratio of the s-(-) to the r-(+) enantiomer of about 3. when administered as multiple once-daily 300 mg doses to healthy subjects or as split-dose regimens to patients with adpkd, tolvaptan's accumulation factor is <1.2. there is marked inter-subject variation in peak and average exposure to tolvaptan with a percent coefficient of variation ranging between 30 and 60%. metabolism and elimination: tolvaptan is metabolized almost exclusively by cyp 3a. fourteen metabolites have been identified in plasma, urine and feces; all but one were also metabolized by cyp 3a and none are pharmacodynamically active. after oral administration of radiolabeled tolvaptan, tolvaptan was a minor component in plasma representing 3% of total plasma radioactivity; the oxobutyric acid metabolite was present at 52.5% of total plasma radioactivity with all other metabolites present at lower concentrations than tolvaptan. the oxobutyric acid metabolite shows a plasma half-life of ~180 h. about 40% of radioactivity was recovered in urine (<1% as unchanged tolvaptan) and 59% in feces (19% as unchanged tolvaptan). following intravenous infusion, tolvaptan half-life is approximately 3 hours. following single oral doses to healthy subjects, the estimated half-life of tolvaptan increases from 3 hours for a 15 mg dose to approximately 12 hours for 120 mg and higher doses due to more prolonged absorption of tolvaptan at higher doses; apparent clearance is approximately 4 ml/min/kg and does not appear to change with increasing dose. specific populations age, gender and race age, gender and race have no effect on tolvaptan pharmacokinetics. hepatic impairment in studies involving patients with hepatic impairment (child-pugh class a-c), but without adpkd; moderate (class a, b) or severe (class c) hepatic impairment decreases the clearance and increases the volume of distribution of tolvaptan. renal impairment in subjects with creatinine clearances ranging from 10 to 124 ml/min administered a single dose of 60 mg tolvaptan, the auc and c max of plasma tolvaptan was increased 90% and 10%, respectively, for subjects with clearances of <30 ml/min compared to subjects with clearances >60 ml/min [see use in special populations (8.7) ]. in adpkd patients with estimated creatinine clearance >60 ml/min, pharmacokinetics were similar to healthy subjects. drug interaction studies: impact of other drugs on tolvaptan strong cyp 3a inhibitors tolvaptan's cmax and auc were, respectively, 3.5 times and 5.4 times as high following ketoconazole 200 mg given one day prior to and concomitantly with 30 mg tolvaptan. moderate cyp 3a4 inhibitors fluconazole: fluconazole 400 mg given one day prior and 200 mg given concomitantly produced an 80% and 200% increase in tolvaptan c max and auc, respectively. grapefruit juice: when 60 mg tolvaptan was taken with 240 ml regular strength grapefruit juice, tolvaptan c max and auc increased 90% and 60%, respectively. cyp 3a inducers rifampin: rifampin 600 mg once daily for 7 days followed by a single 240 mg dose of tolvaptan decreased both tolvaptan c max and auc about 85%. other drugs co-administration of lovastatin, digoxin, furosemide, and hydrochlorothiazide with tolvaptan has no clinically relevant impact on the exposure to tolvaptan. impact of tolvaptan on other drugs cyp 3a substrates co-administration of lovastatin and tolvaptan increases the auc of lovastatin and its active metabolite lovastatin-β hydroxy acid by 40% and 30%, respectively. these are non-clinically significant increases in exposure. p-gp substrates digoxin: digoxin 0.25 mg was administered once daily for 12 days. tolvaptan 60 mg, was co-administered once daily on days 8 to 12. digoxin c max and auc were increased 30% and 20%, respectively. transporter substrates tolvaptan is a substrate of p-gp and an inhibitor of p-gp and bcrp. the oxobutyric acid metabolite of tolvaptan is an inhibitor of oatp1b1 and oat3. co-administration of tolvaptan with rosuvastatin (bcrp substrate) did not have a clinically significant effect on rosuvastatin exposure. rosuvastatin c max and auc t increased 54% and 69%, respectively. administration of rosuvastatin (oatp1b1 substrate) or furosemide (oat3 substrate) to healthy subjects with elevated oxobutyric acid metabolite plasma concentrations did not meaningfully alter the pharmacokinetics of rosuvastatin or furosemide. other drugs co-administration of tolvaptan did not meaningfully alter the pharmacokinetics of warfarin, furosemide, hydrochlorothiazide, or amiodarone (or its active metabolite, desethylamiodarone).

300 and 1000 mg/kg/day (9.7- and 17.3 times the human exposure at the 90/30 mg dose). tolvaptan had no effect on copulation or fertility indices. there were also no effects on the incidences of early or late resorption, dead fetuses, pre- or post-implantation loss, external anomalies, or fetal body weights.

.7- and 17.3 times the human exposure at the 90/30 mg dose). tolvaptan had no effect on copulation or fertility indices. there were also no effects on the incidences of early or late resorption, dead fetuses, pre- or post-implantation loss, external anomalies, or fetal body weights.

after treatment withdrawal and to attend telephone visits at all scheduled visits for up to 36 months. patients who completed treatment at the 3-year visit had treatment interrupted for 2 to 6 weeks to assess renal function post treatment. patients received treatment twice a day (first dose on waking, second dose approximately 9 hours later). patients were initiated on 45 mg/15 mg, and up-titrated weekly to 60 mg/30 mg and then to 90 mg/30 mg as tolerated. patients were to maintain the highest tolerated dose for 3 years, but could interrupt, decrease and/or increase as clinical circumstances warranted within the range of titrated doses. all patients were encouraged to drink adequate water to avoid thirst or dehydration and before bedtime. the primary endpoint was the intergroup difference for rate of change of tkv normalized as a percentage. the key secondary composite endpoint (adpkd progression) was time to multiple clinical progression events of: 1) worsening kidney function (defined as a persistent 25% reduction in reciprocal serum creatinine during treatment from end of titration to last on-drug visit); 2) medically significant kidney pain (defined as requiring prescribed leave, last-resort analgesics, narcotic and anti-nociceptive, radiologic or surgical interventions); 3) worsening hypertension (defined as a persistent increase in blood pressure category or an increased anti-hypertensive prescription); 4) worsening albuminuria (defined as a persistent increase in albumin/creatinine ratio category). at baseline, average estimated glomerular filtration rate (egfr) was 82 ml/min/1.73 m 2 (ckd-epidemiology formula) and mean tkv was 1692 ml (height adjusted 972 ml/m). approximately 35% had an egfr of 90 ml/min/1.73 m 2 or greater, 48% had an egfr between 60 to 89 ml/min/1.73 m 2 , 14% had an egfr of 45 to 60 ml/min/1.73 m 2 , and 3% had an egfr of <45 ml/min/1.73 m 2 . the subjects' mean age was 39 years, 48% were female, 84% were caucasian, 13% were asian, and 1.7% were black or african-american. approximately 80% had hypertension and approximately 71% were taking an agent that acts on the renin-angiotensin system. of the 770 subjects who submitted to genetic analysis in tempo 3:4's open-label extension, 749 (97%) had an identifiable mutation in the pkd1 (656 or 88%), or pkd2 (93 or 12%) gene. the trial met its prespecified primary endpoint of 3-year change in tkv (p<0.0001). the difference in tkv between treatment groups mostly developed within the first year, the earliest assessment, with little further difference in years two and three. in years 4 and 5 during the tempo 3:4 extension trial, both groups received jynarque and the difference between the groups in tkv was not maintained. tolvaptan has little effect on kidney size beyond what accrues during the first year of treatment. the relative rate of adpkd-related events was decreased by 13.5% in tolvaptan-treated patients, (44 vs. 50 events per 100 person-years; hazard ratio, 0.87; 95% ci, 0.78 to 0.97; p=0.0095). as shown in the table below, the result of the key secondary composite endpoint was driven by effects on worsening kidney function and kidney pain events. in contrast, there was no effect of tolvaptan on either progression of hypertension or albuminuria. few subjects in either arm required a radiologic or surgical intervention for kidney pain. most kidney pain events reflected use of a medication to treat pain such as use of paracetamol, tricyclic antidepressants, narcotics and other non-narcotic agents. event tolvaptan placebo hazard ratio, 95% ci total number of events (events per 100 person-years) number of subjects with an event (percentage) total number of events (events per 100 person-years) number of subjects with an event (percentage) composite 1049 (43.9) 572 (59.5) 665 (50.0) 341 (70.6) 0.87 (0.78,0.97) worsening kidney function 44 (1.9) 42 (4.6) 64 (4.8) 61 (12.8) 0.39 (0.26,0.57) kidney pain 113 (4.7) 95 (9.9) 97 (7.3) 78 (16.2) 0.64 (0.47,0.89) onset or progression of hypertension 734 (30.7) 426 (44.3) 426 (32.1) 244 (50.5) 0.94 (0.81,1.09) worsening albuminuria 195 (8.2) 195 (20.3) 103 (7.8) 101 (20.9) 1.04 (0.84,1.28) the third endpoint (kidney function slope) was assessed as slope of egfr during treatment (from end of titration to last on-drug visit). the estimated difference in the annual rate of change in those who contributed to the analysis was 1.0 ml/min/1.73m 2 /year with a 95% confidence interval of (0.6, 1.4). of the subjects enrolled in the trial, 5% of subjects in the tolvaptan arm and 2% in the placebo arm either had missing baseline data or discontinued from treatment prior to the end of the titration visit and hence were excluded from the analysis. in the extension trial, egfr differences produced by the third year of the tempo 3:4 trial were maintained over the next 2 years of jynarque treatment. the efficacy profile was generally consistent across subgroups of interest for this indication; few black or african-american patients were enrolled in the trial. reprise-nct02160145: a phase 3, double-blind, placebo-controlled, randomized withdrawal trial in later-stage adpkd reprise was a double-blind, placebo-controlled randomized withdrawal trial in adult patients (age 18 to 65 years) with chronic kidney disease (ckd) with an egfr between 25 and 65 ml/min/1.73m 2 if younger than age 56 years; or egfr between 25 and 44 ml/min/1.73m 2 , plus egfr decline >2.0 ml/min/1.73m 2 /year if between age 56 to 65 years. subjects were to be treated for 12 months; after completion of treatment, patients entered a 3-week follow-up period to assess renal function. the primary endpoint was the treatment difference in the change of egfr from pre-treatment baseline to post-treatment follow-up, annualized by dividing by each subject's treatment duration. prior to randomization, patients were required to complete sequential single-blind run-in periods during which they received placebo for 1 week, followed by tolvaptan titration for 2 weeks, and then treatment with tolvaptan at the highest tolerated dose achieved during titration for 3 weeks. during the titration period, tolvaptan was up-titrated every 3 to 4 days from a daily oral dose of 30 mg/15 mg to 45 mg/15 mg, 60 mg/30 mg and up to a maximum dose of 90 mg/30 mg. only patients who could tolerate the two highest doses of tolvaptan (60 mg/30 mg or 90 mg/30 mg) for the subsequent 3 weeks were randomized 1:1 to treatment with tolvaptan or placebo. patients were maintained on their highest tolerated dose for a period of 12 months but could interrupt, decrease and/or increase as clinical circumstances warranted within the range of titrated doses. all patients were encouraged to start drinking an adequate amount of water at screening and continuing through the end of the trial to avoid thirst or dehydration. a total of 1519 subjects were enrolled in the study. of these, 1370 subjects successfully completed the pre-randomization period and were randomized and treated during the 12-month double-blind period. because 57 subjects did not complete the off-treatment follow-up period, 1313 subjects were included in the primary efficacy analysis. for subjects randomized, the baseline, average estimated glomerular filtration rate (egfr) was 41 ml/min/1.73 m 2 (ckd-epidemiology formula) and historical tkv, available in 318 (23%) of subjects, averaged 2026 ml. approximately 5%, 75% and 20% had an egfr 60 ml/min/1.73 m 2 or greater, between 30 to 59 ml/min/1.73 m 2 , and between 25 and 29 ml/min/1.73 m 2 , respectively. the subjects' mean age was 47 years, 50% were female, 92% were caucasian, 4% black or african-american and 3% were asian, 93% had hypertension, and 87% of subjects were taking antihypertensive agents affecting the angiotensin converting enzyme or receptor. of the 115 (8%) of subjects who had prior genetic tests, only 54 (47%) knew their results with 48 (89%) of these having pkd1 and 6 (11%) having pkd2 mutations. in the randomized period, the change of egfr from pretreatment baseline to post-treatment follow-up was −2.3 ml/min/1.73 m 2 /year with tolvaptan as compared with −3.6 ml/min/1.73 m 2 /year with placebo, corresponding to a treatment effect of 1.3 ml/min/1.73 m 2 /year (p <0.0001). the key secondary endpoint (egfr slope in ml/min/1.73 m 2 /year assessed using a linear mixed effect model of annualized egfr (ckd-epi)) showed a difference between treatment groups of 1.0 ml/min/ m 2 /year that was also statistically significant (p <0.0001). the efficacy profile was generally consistent across subgroups of interest for this indication; few black or african-american patients were enrolled in the trial.

usp controlled room temperature].

gram [see warnings and precautions (5.2) ]. inform the patient of the following notable requirement: patients must enroll in the program and comply with ongoing monitoring requirements [see warnings and precautions (5.1) ] advise patients that jynarque is only available only through restricted distribution from certified specialty pharmacies participating in the jynarque rems program. therefore, provide patients with the telephone number and web site for information on how to obtain the product [see warnings and precautions (5.2) ]. hypernatremia, dehydration and hypovolemia advise patients to drink water to avoid thirst, throughout the day and night. patients should stop taking jynarque and notify their healthcare provider if they have symptoms or signs of sodium imbalance or dehydration (e.g., dizziness, fainting, weight loss, palpitations, confusion, weakness, gait instability) [see warnings and precautions (5.3) ]. advise the patient that if they cannot drink enough water for any reason (no access to water, cannot sense thirst, unable to maintain hydration due to vomiting, diarrhea) they should stop taking jynarque and inform their health care provider right away [see warnings and precautions (5.3) ] . pregnancy advise pregnant women of the potential risk to a fetus. advise females of reproductive potential to inform their prescriber of a known or suspected pregnancy [see use in specific populations (8.1) ]. lactation advise women not to breastfeed during treatment with jynarque [see use in specific populations (8.2) ].